Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of 84 systematic review(s)/meta-analysis(es). ^[1-84]
• Upadacitinib demonstrated significant effectiveness in adolescents with moderate-to-severe atopic dermatitis (AD), showing improved outcomes on the Eczema Area and Severity Index (EASI) and Investigator's Global Assessment (IGA), particularly at the 200 mg dose compared to lower doses.
• In difficult-to-treat rheumatoid arthritis (RA) patients, upadacitinib showed effectiveness but was not the top performer when compared to tocilizumab and rituximab, indicating variability in treatment response among different populations.
• For axial spondyloarthritis (AxSpA) patients, upadacitinib provided promising results initially, but efficacy waned over time, suggesting the need for continuous assessment in this population.
• Upadacitinib was associated with an increased risk of infections, including herpes zoster, in adult inflammatory bowel disease (IBD) patients, highlighting the importance of monitoring for adverse events in this subgroup.
• In adolescents with AD, upadacitinib was associated with a higher incidence of adverse events (AEs), with odds ratios (OR) of 1.57 for the 15 mg dose and 2.21 for the 30 mg dose, although serious adverse events (SAEs) showed no significant difference compared to placebo.
• Upadacitinib demonstrated no significant safety concerns in RA patients when compared to placebo, with no significant differences in SAEs among various Janus kinase (JAK) inhibitors.
• In patients with ulcerative colitis (UC), upadacitinib was linked to an increased risk of infections and herpes zoster, indicating the need for continuous monitoring of long-term safety.
• Among psoriatic arthritis (PsA) patients, upadacitinib showed an increased risk of infections, but no significant differences in SAEs were reported across different JAK inhibitors, suggesting similar safety profiles.